AstraZeneca at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
AstraZeneca takes part in 5 sessions at Antibody Engineering 2026 in San Diego. Its program centers on antibody-drug conjugates, including how translational medicine drives their clinical success, and on T cell engagers. Highlights include a CD30 conjugate that carries two different drug payloads using non-natural amino acids, and a CD8-guided T cell engager with a wide safety margin in preclinical studies.
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases. | Talk Sun Dec 13 11:00am–11:45am Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Talk Wed Dec 16 2:10pm–2:15pm Talk Wed Dec 16 2:15pm–2:45pm |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction